Profile data is unavailable for this security.
About the company
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
- Revenue in USD (TTM)141.83m
- Net income in USD-406.24m
- Incorporated2020
- Employees1.00k
- LocationGrail Inc1525 O'brien DriveMENLO PARK 94025United StatesUSA
- Phone+1 (650) 771-9796
- Fax+1 (302) 655-5049
- Websitehttps://grail.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.31bn | 2.90k | -- | 3.27 | -- | 3.64 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Alumis Inc | 22.12m | -245.15m | 3.44bn | 233.00 | -- | 7.21 | -- | 155.29 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
| Erasca Inc | 0.00 | -127.69m | 3.70bn | 103.00 | -- | 9.75 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| ACADIA Pharmaceuticals Inc | 1.05bn | 261.17m | 3.84bn | 653.00 | 14.62 | 4.19 | 13.95 | 3.67 | 1.55 | 1.55 | 6.21 | 5.42 | 0.9075 | 1.88 | 9.78 | 1,603,550.00 | 22.64 | -13.15 | 32.50 | -16.74 | 91.92 | 94.49 | 24.94 | -16.00 | 2.94 | -- | 0.00 | -- | 31.85 | 23.08 | 469.50 | -- | -14.26 | -- |
| Arcellx Inc | 35.90m | -217.90m | 3.89bn | 163.00 | -- | 8.81 | -- | 108.31 | -3.92 | -3.92 | 0.6462 | 7.63 | 0.0505 | -- | 9.57 | 220,233.10 | -30.67 | -27.24 | -37.39 | -32.13 | -- | -- | -607.01 | -212.50 | -- | -- | 0.00 | -- | -2.16 | -- | -51.86 | -- | 28.52 | -- |
| Grail Inc | 141.83m | -406.24m | 4.04bn | 1.00k | -- | 1.67 | -- | 28.50 | -11.63 | -11.63 | 4.06 | 61.94 | 0.0496 | -- | 9.01 | 141,827.00 | -14.21 | -49.71 | -14.65 | -50.85 | 46.88 | 39.69 | -286.43 | -3,510.18 | -- | -- | 0.00 | -- | 34.90 | -- | -38.30 | -- | 9.34 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.06bn | 59.00 | -- | 11.77 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 4.21bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 4.28bn | 113.00 | -- | 6.04 | -- | 1,969.90 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 4.30bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.47bn | 196.00 | -- | 6.63 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| Amicus Therapeutics, Inc. | 598.70m | -14.06m | 4.49bn | 499.00 | -- | 19.14 | -- | 7.50 | -0.0458 | -0.0458 | 1.94 | 0.7469 | 0.7234 | 0.4175 | 5.65 | 1,199,808.00 | -1.70 | -23.63 | -2.17 | -28.66 | 89.77 | 89.34 | -2.35 | -53.29 | 2.09 | 0.8067 | 0.6298 | -- | 32.29 | 23.72 | 62.99 | -- | -29.23 | -- |
| Crinetics Pharmaceuticals Inc | 1.54m | -423.10m | 4.52bn | 437.00 | -- | 4.20 | -- | 2,943.19 | -4.53 | -4.53 | 0.0165 | 11.34 | 0.0014 | -- | 0.2622 | 3,512.59 | -39.66 | -36.96 | -42.19 | -39.20 | -- | -- | -27,563.32 | -7,785.98 | -- | -- | 0.00 | -- | -74.11 | -2.73 | -39.10 | -- | 50.86 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 17 Nov 2025 | 2.18m | 5.59% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.12m | 5.45% |
| PRIMECAP Management Co.as of 30 Sep 2025 | 2.02m | 5.18% |
| CRCM LPas of 06 Oct 2025 | 1.80m | 4.62% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.74m | 4.46% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 1.63m | 4.18% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.32m | 3.38% |
| Arbiter Partners Capital Management LLCas of 30 Sep 2025 | 1.04m | 2.66% |
| Sessa Capital IM LPas of 30 Sep 2025 | 786.14k | 2.02% |
| Geode Capital Management LLCas of 30 Sep 2025 | 730.25k | 1.87% |
